Successful treatment of retroperitoneal infantile hemangioendothelioma with Kasabach-Merritt syndrome using steroid, alpha-interferon, and vincristine.
Infantile hemangioendothelioma (IHE) is a rare benign vascular tumor with potentially life-threatening complications. Various therapeutic options have been recommended according to the site, extent, and behavior of the IHE. Because of the slow and unpredictable response to treatment with using a single drug in critically ill patients, there is a tendency to administer drugs in combination to treat this disease. Here, we report on a 1-month-old female infant who had a retroperitoneal IHE with Kasabach-Merritt syndrome and she was successfully treated with a combination of steroid, interferon-alpha, and vincristine.
Yoon
Hoi Soo
HS
Department of Pediatrics, Kyung Hee University Medical Center, Seoul, Korea.
Lee
Jae Hee
JH
Moon
Hyung Nam
HN
Seo
Jong Jin
JJ
Im
Ho Joon
HJ
Goo
Hyun Woo
HW
D003937:Diagnosis, Differential; D004211:Disseminated Intravascular Coagulation / Q000150:complications / Q000188:drug therapy*; D004359:Drug Therapy, Combination; D005260:Female; D006390:Hemangioendothelioma / Q000188:drug therapy*; D006801:Humans; D007231:Infant, Newborn; D016898:Interferon-alpha / Q000627:therapeutic use*; D008775:Methylprednisolone / Q000627:therapeutic use*; D012186:Retroperitoneal Neoplasms / Q000188:drug therapy*; D013577:Syndrome; D016896:Treatment Outcome; D014750:Vincristine / Q000627:therapeutic use*
D016898:Interferon-alpha; D014750:Vincristine; D008775:Methylprednisolone